Study Group: Xopenex Prescribers (US)(?)
Council Members in this Study Group: 83
Request a survey with this Study Group
Leading Experts in this Study Group
President
PSS Clinical Research
Warren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia. He is the Medical Director of the Critical Care Unit at DeKalb Medical Center in Decatur, Medical Director of Southern Sleep Technologies and the Co-Director of two sleep disorders centers in the Atlanta...
Robert Aris, MDAssociate Professor of Medicine
University of North Carolina Chapel Hill - CC
Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...
Michael Blaiss, MDPartner
Allergy & Asthma Care
Michael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes research in allergic disorders, especially...
Associate Physician in Pulmonary and Critical Care
BRIGHAM AND WOMEN'S HOSPITAL
Michael Wechsler, MD, is an Associate Physician in the Pulmonary and Critical Care Division of Brigham and Women's Hospital in Boston and is on the faculty at Harvard Medical School. He is a member of the Steering Committee of the NIH's Asthma Clinical Research Network and is active in both basic and...
Director
Allergy and Asthma Specialists Medical Group & Research Center
Steven Weinstein, MD, is the Director of Allergy and Asthma Specialists Medical Group and Research Center, California. He also holds an academic appointment as Clinical Professor of Allergy and Immunology in the Department of Pediatrics at the University of California, Irvine, School of Medicine. Dr....
Related Study Groups
| Study Group Name | Members |
|---|---|
| Physicians who Treat Asthma (US) | 442 |
| Pulmonologists (US) | 747 |
| Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD) | 192 |
| Pediatricians (US) | 1650 |
| Allergists (US) | 404 |
| Xolair Prescribers for Asthma (US) | 65 |
| Physicians who Treat Insomnia (US) | 508 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients. This is important because the definition of functional class II is that a patient has a sight...
Electronic Health Records (EHR) are like a marriage, but are difficult to implement. They are expensive, time-consuming and require a paradigm shift from ALL employees of the practice. Half of all attempts fail; similar to getting married. They do save costs of transcription and filing/pulling...
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...
we really have had little luck with straterra in our office. Even at high doses, the drug rarely does the trick
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- Physician - Division Head
- Partner
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

